FINANCE
Healthcare Stocks: What Analysts Are Saying About Pfizer and Oneview
Wed Jul 30 2025
Pfizer: Mixed Reviews and Moderate Buy Consensus
- Analyst Rating: Justin Smith from Bernstein maintains a "Hold" rating.
- Price Target: $30.00 (vs. last week's close of $24.79).
- Other Opinions: Another analyst downgrades Pfizer to "Hold" with a price target of $26.00.
- Consensus: "Moderate Buy" with an average price target of $28.40, indicating a potential 13.7% increase from the current stock price.
Oneview Healthcare: Bullish Sentiment Despite Analyst Ranking
- Analyst Rating: Martyn Jacobs from Bell Potter gives a "Buy" rating.
- Price Target: A$0.34 (vs. last week's close of $0.16, the highest in the past year).
- Consensus: "Moderate Buy" with an average price target of $0.23.
- Caution: Jacobs is ranked low among analysts, which may influence investor decisions.
Key Considerations for Investors
- Market Trends: Broader economic conditions and industry performance.
- Company Performance: Individual company metrics and growth prospects.
- Research: Encouraged to conduct thorough research before investing.
continue reading...
questions
If Pfizer's stock hits $30, will Justin Smith from Bernstein throw a party or just maintain his Hold rating?
Is Oneview Healthcare's stock price of $0.16 a sign that it's the next big thing or just a penny stock playing hard to get?
What factors might cause Pfizer's stock to deviate from the predicted 13.7% upside?
actions
flag content